Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a ...

Clinical Development Programs:

 • Zunsemetinib, an investigational oral small molecule MK2 inhibitor:
Currently being developed as a potential treatment for immuno-inflammatory disease s

 • ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor:
Currently being developing as a potential treatment for moderate to severe atopic dermatitis (AD)

 • ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor:
Currently being developed as a potential treatment for T cell-mediated autoimmune diseases

Preclinical Development Program

 • ATI-2231, an investigational oral MK2 inhibitor compound:
Currently being explored as a potential treatment for pancreatic cancer and metastatic breast cancer as well as in preventing bone loss in patients with metastatic breast cancer

Financial Highlights:

Liquidity and Capital Resources

As of December 31, 2022, Aclaris had aggregate cash, cash equivalents and marketable securities of $229.8 million compared to $225.7 million as of December 31, 2021. Aggregate cash, cash equivalents and marketable securities as of December 31, 2022 included proceeds received during the fourth quarter under a license agreement with Pediatrix Therapeutics, Inc. (Pediatrix).

Aclaris continues to anticipate that its cash, cash equivalents and marketable securities as of December 31, 2022 will be sufficient to fund its operations through the end of 2025, without giving effect to any potential business development transactions or financing activities.

Financial Results

Fourth Quarter 2022

Full Year 2022

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ drug candidates, including the timing of its clinical trials, availability of data from those trials, and regulatory filings, the identification of novel development candidates through Aclaris’ KINect discovery engine, and its belief that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2025. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2022, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, 2022 2021 2022 2021 Revenues: Contract research $866 $1,274 $4,395 $5,830 Licensing 6,722 197 25,100 809 Other 165 30 257 122 Total revenue 7,753 1,501 29,752 6,761 Costs and expenses: Cost of revenue (1) 877 1,149 4,023 4,713 Research and development (1) 21,072 14,102 77,813 43,813 General and administrative (1) 7,146 6,943 25,133 23,619 Licensing 637 — 7,937 — Revaluation of contingent consideration 7,100 2,200 4,700 24,339 Total costs and expenses 36,832 24,394 119,606 96,484 Loss from operations (29,079) (22,893) (89,854) (89,723)Other income (expense), net 1,444 89 2,946 (1,142)Net loss $(27,635) $(22,804) $(86,908) $(90,865)Net loss per share, basic and diluted $(0.41) $(0.37) $(1.33) $(1.60)Weighted average common shares outstanding, basic and diluted 66,685,580 61,227,800 65,213,944 56,730,583 (1) Amounts include stock-based compensation expense as follows: Cost of revenue $314 $194 $1,151 $981 Research and development 1,517 897 3,745 3,866 General and administrative 2,982 2,760 10,143 9,213 Total stock-based compensation expense $4,813 $3,851 $15,039 $14,060 

Aclaris Therapeutics, Inc.
Selected Consolidated Balance Sheet Data
(unaudited, in thousands, except share data) December 31, 2022 December 31, 2021 Cash, cash equivalents and marketable securities $229,813 $225,656 Total assets $254,596 $251,211 Total current liabilities $21,938 $22,931 Total liabilities $56,975 $53,870 Total stockholders' equity $197,621 $197,341 Common stock outstanding 66,688,647 61,228,446 

Aclaris Therapeutics, Inc.
Selected Consolidated Cash Flow Data
(unaudited, in thousands) Year Ended

December 31, 2022 Year Ended

December 31, 2021 Net loss $(86,908) $(90,865)Depreciation and amortization 797 923 Stock-based compensation expense 15,039 14,060 Revaluation of contingent consideration 4,700 24,339 Loss on extinguishment of debt — 752 Changes in operating assets and liabilities (1,195) (1,343)Net cash used in operating activities $(67,567) $(52,134)

Aclaris Therapeutics Contact:

Robert A. Doody Jr.
Vice President, Investor Relations
484-639-7235
rdoody@aclaristx.com